The forefront of nuclear medicine is undergoing a profound revolution, with the core being an extremely rare but powerful radioactive isotope - actinium-225 (225Ac). Recently, scientists at Oak Ridge National Laboratory (ORNL) in Tennessee are working on extracting and developing this substance, which is hailed as one of the most promising new weapons against cancer. ORNL's 225Ac mainly originates from the decay of thorium-229 (229Th), hence this production system is known in the industry as "Thorium Cow".  
Although ORNL's 229Th generator has limited 225Ac production, its long-term stable supply has laid the historical foundation for the transition of 225Ac from laboratory to clinical research due to the half-life of the parent nuclide 229Th, which is as long as 7340 years. This reflects the foresight of the nuclear medicine community in the strategic reserve of rare nuclide resources. Targeted Alpha Therapy (TAT) utilizes the high-energy properties of 225Ac to attach it to highly specific targeting molecules, such as antibodies or peptides. These targeted molecules can recognize and lock onto specific antigens on the surface of cancer cells. Once drug molecules attach, 225Ac will release highly lethal alpha (α) particles, achieving precise clearance of tumor cells while maximizing protection of surrounding healthy tissues.
The clinical application of 225Ac is driving radionuclide therapy into a new era. Traditional radionuclide therapy, such as the 177Lu therapy widely used in prostate cancer and neuroendocrine tumors, mainly relies on beta particles. Beta particles belong to Low Linear Energy Transfer (LET) radiation, which has lower energy and longer range (millimeter level) in tissues. The energy damage caused by this mechanism of action is repairable and may lead to cancer cells developing drug resistance or escaping killing.  
In contrast, the alpha particles released by 225Ac have extremely high LET. Scientists describe the difference between alpha particles and beta particles as a comparison between a fully loaded semi-trailer and a 10 pound dumbbell. Alpha particles are nearly 8000 times larger in mass than beta particles and can release enormous energy within a very short range (usually only penetrating the diameter of a few cells). This high-intensity localized energy

1. The scientific basis of Targeted Alpha Therapy (TAT): precise strikes from high-energy physics
1.1 Nuclear Physical Properties and Unique Advantages of 225Ac
The half-life of 225Ac is approximately 9.920 days, and it has ideal properties in radiopharmaceuticals. This 10 day half-life is long enough to support complex pharmaceutical processes, drug labeling, transportation, and allow sufficient time for drugs to target tumors and accumulate in the patient's body; It is short enough to ensure that the radioactive drug can completely decay and be cleared from the body within a few months after the treatment is completed.  
Its core therapeutic advantage lies in the "quadruple alpha particle warhead" mechanism of its decay chain. During the decay of 225Ac to stable 209Bi, it continuously releases four high-energy alpha particles. This mechanism provides a powerful therapeutic multiplier effect. Compared to the sub nuclide 213Bi of 225Ac (which has a half-life of only 46 minutes and releases one alpha particle), the continuous bombardment of multiple alpha particles greatly enhances the therapeutic efficacy. In vitro cytotoxicity studies have shown that to achieve the LD50 of 213Bi drug, the required radioactivity of 225Ac is several orders of magnitude lower. This indicates that the pharmacological advantage of 225Ac lies not only in the high LET of the alpha particles themselves, but also in its physical half-life and decay chain design, making it an efficient in vivo micro particle accelerator.
1.2 Comparison of biological killing mechanisms between alpha particles and beta particles (high LET vs. low LET)
There are fundamental differences in the biological mechanisms of action between alpha particles and beta particles. Beta particles (low LET) mainly generate free radicals through indirect ionization, causing damage to cellular DNA. This low LET damage is often repairable, and cancer cells need to receive multiple, cumulative blows to reach a lethal dose.  
In sharp contrast, alpha particles (high LET), due to their enormous physical size and high-energy deposition characteristics, can directly and efficiently induce complex DNA double strand breaks (DSBs) within a very short range (only a few cell diameters). DSBs are a type of cellular damage that is difficult to repair. The biological advantage of high LET (high relative biological effect RBE) enables it to effectively kill hypoxic or slow dividing cancer cells that are resistant to conventional radiotherapy (including beta therapy). The intergenerational leap of this mechanism enables 225Ac to efficiently and locally clear small lesions that are difficult to reach with traditional therapies.

2. Strategic Resources and Industrial Bottlenecks: Modernization Transformation of 225Ac Production
2.1 The dilemma of supply shortage and the limitations of "thorium cattle"
The scarcity of 225Ac supply is the biggest obstacle to its clinical popularization. It is known as one of the rarest drugs on Earth, and the estimated annual supply of 225Ac is only enough for about 1000 cancer treatments.  
The traditional 229Th generator method (also known as "thorium cow") has historically been the main source of 225Ac, especially produced and supplied by ORNL for a long time. Although this method has the advantage of high product purity, its production speed is extremely slow due to the half-life of 229Th being as long as 7340 years, and there is a strict upper limit to the yield. The surge in global clinical research and demand (covering prostate cancer, neuroendocrine tumor, breast cancer, lymphoma and other indications) has made the supply system relying on generator method unable to meet the market demand. 
2.2 The Rise of Accelerator Production Path: Scale and Technological Challenges
To achieve large-scale supply of 225Ac, the global research community is vigorously developing accelerator production pathways, which utilize high-energy proton beams to bombard target materials such as 232Th or 226Ra to synthesize 225Ac. This method has enormous potential production capacity and is a hope for meeting future commercial scale demands.  
However, accelerator production comes with significant challenges in nuclear chemistry and engineering. The fission reaction caused by high-energy protons does not only produce 225Ac, but also produces over 400 nuclides simultaneously. Therefore, how to efficiently and high-purity separate and purify the target product in extremely high radiation dose environments is the core technological bottleneck that determines the feasibility of production. During the separation and purification process, it is necessary to strictly control and separate the long-lived beta decay nuclide 227Ac to prevent it from causing long-term systemic radiation toxicity to patients, which is a prerequisite for drug safety.  
International research teams are tackling these challenges. For example, the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences realized the preparation of 225Ac by bombarding the 232Th target with the beam of the Lanzhou Heavy Ion Research Facility (HIRFL). The team has achieved efficient separation under high radiation doses through a pioneering remote control system for target robots and a self-developed fully automated separation and multi chromatographic combination device, increasing the purity of radioactive nuclei to over 98% and radiochemical purity to over 99%. This indicates that the success of large-scale production of 225Ac depends on the precise combination of nuclear chemistry, automation engineering, and nuclear physics.  
2.3 Commercialization and Compliance of Supply Chain
The global industry is actively promoting the commercialization and compliance of the 225Ac supply chain. Cardinal Health announced at the end of 2024 that it will begin weekly routine production of 225Ac through its Therapeutic Diagnostics Advancement Center. The company has become the world's first to provide commercial scale 225Ac materials that comply with cGMP (Good Manufacturing Practice) standards, marking a critical structural shift in 225Ac supply from research grade to pharmaceutical grade.  
Meanwhile, the US Department of Energy (DOE) has announced that its accelerator produced 225Ac will be used for FDA approved clinical trials for the first time in the summer of 2025. This cooperation has opened up new stable supply channels, which is of milestone significance for promoting the research and development of radiopharmaceuticals and cancer treatment. These commercialization and technological breakthroughs mean that the 225Ac market is shifting from supply limited to demand driven, and the improvement of global supply capacity is the decisive factor for the popularization of TAT therapy in the next decade.

3. Clinical translation and key data: the savior of refractory tumors
3.1 Precise targeting of prostate cancer: 225Ac PSMA series
Prostate specific membrane antigen (PSMA) is one of the most promising targets in the treatment of prostate cancer (PCa). 225Ac is used to treat metastatic castration resistant prostate cancer (mCRPC) by binding to PSMA targeting molecules (such as PSMA-617 or PSMA-I&T) and antibodies (such as J591, BAY3546828). Research has shown that the labeling rate of 225Ac with prostate cancer targeting molecule PSMA-617 can reach up to 99%.  
The clinical trial results show that 225Ac-PSMA-I&T has comparable anti-tumor effects to 225Ac-PSMA-617. More importantly, 225Ac PSMA therapy showed significant efficacy even after patients failed treatment with 177Lu-PSMA-617. This confirms that the high LET killing mechanism of alpha particles can overcome the resistance bottleneck caused by beta particle therapy, providing a highly promising salvage treatment option for advanced and refractory PCa patients.  
3.2 Milestones of Neuroendocrine Tumors (NETs): 225Ac DOTATATE
Neuroendocrine tumors (NETs) are another important area of nuclear therapy. Although 177Lu DOTATATE choroidal receptor peptide radionuclide therapy (PRRT) has been widely used, there are still some patients who have no response or disease progression to 177Lu treatment.
225Ac DOTATATE TAT has demonstrated significant long-term clinical benefits in patients with previously intractable gastrointestinal pancreatic neuroendocrine tumors (GEP NETs) treated with 177Lu. A long-term outcome analysis showed that patients achieved significant clinical benefits after receiving 225Ac DOTATATE treatment, and the associated treatment-related toxicity was transient and acceptable. Key data indicates that the median overall survival (OS) has not yet been reached, and the probability of OS at 24 months is as high as 70.8%; The median progression free survival (PFS) was not achieved, with a probability of 67.5% at 24 months. This result strongly demonstrates that 225Ac DOTATATE TAT can provide significant survival benefits to patients through mechanism intergenerational leaps after the failure of beta particle therapy, promoting its positioning as a salvage therapy.  
3.3 Exploration of Other Indications and Drug Design
In addition to prostate cancer and NETs, 225Ac targeted therapy is also used to treat leukemia, breast cancer, lymphoma and other cancers. For example, after using the experimental 225Ac drug on 18 patients with acute myeloid leukemia, their condition significantly improved.  
In terms of drug research and development, the team of the Institute of Modern Physics of the Chinese Academy of Sciences successfully prepared the 225Ac labeled original targeting polypeptide DOTA-HSV, with a labeling rate of 87%. The inhibitory effect of this drug on the migration and invasion of non-small cell lung cancer A549 cells is significantly stronger than that of free 225Ac with the same activity. This demonstrates the enormous potential and diversity of targeted carrier drug design.

4. Dosage, Biodistribution, and Safety Considerations: Balancing Accuracy and Risk
Efficient 225Ac therapy must be based on highly cautious toxicity management. The high LET property of alpha particles, although capable of efficiently killing cancer cells, also has strong destructive power on off target healthy tissues.
4.1 Inherent contradiction between efficient killing and off target toxicity
The main non targeted toxicity risks include impaired salivary gland function (especially PSMA targeted drugs) and renal toxicity. Due to the high RBE of alpha particles, even small dose deviations or off target enrichment can lead to severe organ damage. Therefore, drug design and treatment plans must strive to maximize tumor enrichment while minimizing exposure to healthy organs.  
4.2 Migration and systematic exposure of radioactive nuclides
The migration problem caused by the short half-life of neutron nuclides (such as 221Fr and 213Bi) in the 225Ac decay chain is the core challenge of 225Ac toxicity management. If 225Ac dissociates from the targeted carrier in the body, the free daughter nuclide will enter the bloodstream, causing systemic radiation exposure. Once high LET alpha particles are off target, they will cause significant damage to healthy tissues.  
Therefore, successful 225Ac drugs must use highly stable chelating agents to prevent the dissociation of 225Ac and its daughter nuclides in the body. In addition, clinical doctors must consider the biological distribution and serum clearance rate of radioactive drugs when selecting them. For targeted molecules with slow blood clearance, if their decay nuclide is radioactive, the risk of systemic toxicity will increase. Research suggests that for some drugs with slow serum clearance rates, they may actually benefit from using non radioactive isotopes (such as 213Bi) to minimize systemic exposure.  
4.3 Individualized dosimetry and treatment optimization
The traditional uniform dose prescription carries inherent risks in 225Ac therapy. This pattern may lead to insufficient tumor dose in specific patients or excessive dose to off target organs (such as the kidneys), resulting in unnecessary toxicity.  
Future treatments must shift towards individualized dosimetry. Clinical doctors need to develop and apply customized dose prescriptions based on advanced imaging and biological distribution analysis, adjust radiation dose according to the distribution, volume, and actual behavior of drugs in the body of metastatic tumors, optimize the retention time of 225Ac inside the tumor and the clearance time in healthy organs. This personalized management model is a necessary guarantee for balancing the efficacy and safety of 225Ac and enabling it to be widely used in clinical practice.